Description
Rapidly accelerated fibrosarcoma (Raf) kinase is a serine/threonine kinase and component of the MAPK/ERK signaling pathway.{54387,54388} Upon activation by upstream RAS signaling, Raf dimerizes and phosphorylates MEK1 leading to activation of transcription factors for cell growth, proliferation, and survival.{54388} Raf exists as three isoforms, A-RAF, B-RAF, and C-RAF, that all consist of three conserved regions (CRs) with domain-specific functions.{54387} CR1 contains a cysteine-rich domain and a RAS-binding domain, CR2 is essential for negative regulation through inhibition of phosphorylation sites, and CR3 is the kinase domain. B-RAF is the most prominent isoform, expressed in most tissues, and localized to the cytosol. A single amino acid substitution of glutamic acid for valine at codon 600 in the kinase domain (B-RAFV600E) is an activating mutation that is found in melanoma and non-small cell lung cancer (NSCLC), as well as breast, thyroid, colorectal, and ovarian cancers.{54387,54388} B-RAFV600E is associated with early-stage ovarian cancer, as well as with increased risk of brain metastasis and shorter survival in melanoma.{54387,54389} Cayman’s B-RAFV600E Monoclonal Antibody can be used for ELISA, immunocytochemistry (ICC), immunohistochemistry (IHC), and Western blot (WB) applications.
Synonyms: B-RAF Proto-oncogene|Proto-oncogene B-RAF|RAFB1|Serine/Threonine Kinase|V-Raf Murine Sarcoma Viral Oncogene Homolog B
Immunogen: Peptide corresponding to B-RAFV600E
Formulation: 100 µg of protein A-affinity purified monoclonal antibody
Isotype: IgG
Applications: ELISA, ICC, IHC, WB
Origin:
Stability: 365 days
Application|ELISA||Application|Immunocytochemistry||Application|Immunohistochemistry||Application|Western Blot||Product Type|Antibodies|Monoclonal Antibodies||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Cancer|Cell Signaling|ERK/MAPK Signaling
